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Pomalidomide (POM), a potent anticancer thalidomide analogue was characterized in terms of cyclodextrin
complexation to improve its aqueous solubility and maintain its anti-angiogenic activity. The most promising
cyclodextrin derivatives were selected by phase-solubility studies. From the investigated nine cyclodextrins –
differing in cavity size, nature of substituents, degree of substitution and charge – the highest solubility increase
was observed with sulfobutylether-β-cyclodextrin (SBE-β-CD). The inclusion complexation between POM and SBE-
β-CD was further characterized with a wide variety of state-of-the-art analytical techniques, such as nuclear
magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR), circular dichroism spectroscopy, fluores-
cence spectroscopy as well as X-ray powder diffraction method (XRD). Job plot titration by NMR and the AL-type
phase-solubility diagram indicated 1:1 stoichiometry in a liquid state. Complementary analytical methods were
employed for the determination of the stability constant of the complex; the advantages and disadvantages of the
different approaches are also discussed. Inclusion complex formation was also assessed by molecular modelling
study. Solid state complexation in a 1:1 M ratio was carried out by lyophilization and investigated by IR and XRD.
The complex exhibited fast-dissolution with immediate release of POM, when compared to the pure drug at acidic
and neutral pH. Kinetic analysis of POM release from lyophilized complex shows that Korsmeyer-Peppas and
Weibull model described the best the dissolution kinetics. The cytotoxicity of the complex was tested against the
LP-1 human myeloma cell line which revealed that supramolecular interactions did not significantly affect the
anti-cancer activity of the drug. Overall, our results suggest that the inclusion complexation of POM with SBE-
β-CD could be a promising approach for developing more effective POM formulations with increased solubility.1. Introduction
Multiple myeloma is a cancer of the white blood cells, characterized by
an increase of abnormal plasma cells in the bone marrow and monoclonal
proteins in the serum, often with osteolytic bone lesions. The thalidomide
analogue immunomodulatory drugs are first-line treatment options of
multiple myeloma in combination with bortezomib and dexamethasone-univ.hu (G. Toth).
July 2021; Accepted 12 July 202
evier Ltd. This is an open access[1]. One of the newer members of the immunomodulatory class of drugs is
pomalidomide (POM). POM ((RS)-4-Amino-2-(2,6-dioxopiperidin-3-yl)
isoindole-1,3-dione, Figure 1) was approved in 2013, by the FDA and EMA
as a treatment for relapsed and refractory multiple myeloma. It has been
approved for use in patients who have received at least two prior therapies
including lenalidomide and bortezomib and have demonstrated disease
progression on or within 60 days of completion of the last therapy [2].1
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Chemical structure of pomalidomide.
Z.-I. Szabo et al. Heliyon 7 (2021) e07581POM has a low oral bioavailability mainly due to its poor solubility in
water. In rats and monkeys, the oral bioavailability was in the range of
13%–15% following a 100 mg/kg dose. However, the bioavailability in
monkeys was high (approximately 100%) at a lower dose of 2 mg/kg,
indicating that the extent of absorption is solubility limited [3].
Increasing the solubility of POM could enhance its bioavailability.
Consequently, the dose and side effects could be reduced, and possibil-
ities of novel parenteral formulations would also arise.
Solubility enhancement can be achieved by various methods, such as
solid dispersion, size reduction, cosolvency, polymorphism, formation of
water-soluble prodrugs or complexes [4]. Cyclodextrin (CD) complexa-
tion is one of the most extensively investigated methods to improve drug
solubility and concomitantly, also bioavailability [5].
The conical structure of CDs and the outside orientation of the hydroxyl
groups confer unique physicochemical properties to these cyclic sugars,
capable of being solubilized in an aqueous medium and at the same time
encapsulating hydrophobic molecules in their internal cavity space. CD
complexation of pharmaceuticals can result in improved properties of the
guest molecules, such as improved solubility, stability, masking of unde-
sirable properties, protection against oxidation, light-induced reactions,
and loss by evaporation [6]. The native CDs contain six, seven or eight
D-glucose units and are named α-, β- and γ-CD, respectively. Nowadays
hundreds of semi-synthetic derivatives of native CDs are available in the
market, which extend the range of applications of these molecules [7].
In our recent work CDs were used as chiral selectors to separate POM
enantiomers in capillary electrophoresis and high-performance liquid
chromatography [8, 9]. In the latter case the β-CD-based chiral stationary
phase was applied, and the inclusion complex was characterized to shed
light on the underlying mechanisms of enantiodiscrimination [9].
To the best our knowledge, to date, no previous method regarding sol-
ubility improvement of POM has been described. The solubility of lenali-
domide, another commercially available thalidomide analog, was
improved via cocrystal formationwith urea and 3,5-dihydroxybenzoic acid
[10]. The most studied structurally related drug is the parent molecule,
thalidomide. Earlier works prove that CD complexation can improve the
solubility and stability of thalidomide [11, 12]. Moreover, thalidomide
administered orally in combination with sulfobutylether-β-CD (SBE-β-CD),
led to a significant delay in tumor progression because of improved cellular
drug absorption and distribution through solubilization in mice [13].
The present work focuses on the characterization of complex forma-
tion between POM and various CDs focusing mostly on solubility
enhancement and dissolution profile. Subsequently, the in vitro anti-
proliferative effects were also investigated to verify the effect of the CD
complexation on cytotoxicity. The proposed information could offer a
molecular basis for a novel, improved drug formulation.
2. Materials and methods
2.1. Materials
POM was obtained from Beijing Mesochem Technology Co. Ltd.
(Beijing, China). D2O, DMSO-d6 and DMSO were ordered from Sigma-2
Aldrich Hungary (Budapest, Hungary). All native CDs (α-, β- and γ-CD)
and their derivatives (hydroxypropyl-β-CD (HP-β-CD) with different de-
grees of substitution (DS) 3, 4.5, 6; randomly methylated-β-CD DS~12
(RAMEB), permethylated-β-CD (TRIMEB), sulfobutylether-β-CD DS~7
(SBE-β-CD)) were the products of Cyclolab R&D Ltd. (Budapest,
Hungary). All other chemicals used were of analytical grade from com-
mercial suppliers. Ultrapure, deionized water was prepared by a Milli-Q
Direct 8 Millipore system (Milford, MA, USA).2.2. Physico-chemical characterization
The acid dissociation constant of POM was determined by 1H NMR
titration using dichloroacetic acid, sarcosine, and sodium acetate as in situ
pH indicators [14]. The ionic strength was 1M. The n-octanol/water
partition coefficient (P) was determined by the classical stir-flask method
based on our earlier published methods [15] at three different n-octa-
nol/water phase ratios (0.5, 1, and 2). The partitioning was performed at
25 C and pH 7. The value of thermodynamic solubility was measured as
indicated in phase-solubility methods.2.3. Phase-solubility methods
Phase-solubility analysis was performed according to the method
described by Higuchi and Connors [16]. Excess amount of POM (10 mg)
was added to 3 mL water (without any buffer) containing increasing
concentrations of CDs (0, 5, 10, 15, 20, 25, 30 mM for each CDs, except
β-CD, where 0, 2, 4, 8, 10, 12 mM were used, due to its low solubility in
water). The obtained suspensions were stirred for 24 h at 25 1 C. POM
concentrations were measured from the filtered suspensions (PVDF 0.22
μm filter membrane) spectrophotometrically on a Jasco V-550 instru-
ment (Jasco Ltd., Tokyo, Japan) at 390 nm. Three parallel measurements
were carried out in all cases. The apparent stability constant K1:1 was
calculated from the slope of the initial linear portion of POM concen-
tration against CD concentration profiles assuming 1:1 complex forma-
tion in each case (Eq. 1):
K1:1 ¼ tgαS0ð1 tgαÞ (1)
Where tgα is the slope of phase solubility plot, So is the intrinsic solubility
of POM, determined experimentally. Three parallel measurements were
performed in each case.2.4. Circular dichroism and fluorescence spectroscopy
Electronic circular dichroism and fluorescence experiments were
performed on a Jasco J-810 spectropolarimeter (Jasco Ltd., Tokyo,
Japan) in cylindrical cuvettes. POMwas dissolved in DMSO to form 0.1M
stock solutions, which were further diluted with distilled water to 0.001
M. The POM concentration was constant during the titration, while the
CD concentration increased until 1:30 POM:CD ratio. The spectra were
accumulated three times with a bandwidth of 2 nm and a scanning step of
0.1 nm at a scan speed of 100 nm/min. The calculation of the stability
constant for the 1:1 M ratio complex had been published previously [17].
The same method has been used for the determination of POM –
SBE-β-CD stability constant.
The parallel measured fluorescence intensity can also be used for the
calculation of the complex stability constant (K), but the own, specific
fluorescence of the guest and the complex should also be considered, thus
the measured signal is less selective than ellipticity. In this case, the
measured signal is the sum of the fluorescent intensity of the guest and
the complex. Both the molecule and the complex have a different
intrinsic fluorescent activity, IPOM for the guest and Icomplex for the com-
plex. The measured fluorescent activity is a linear combination of the two
intensities as Eq. (2) described.
Z.-I. Szabo et al. Heliyon 7 (2021) e07581I¼ IPOM*½POME þ ICD*½complex (2)where IPOM and ICD are the intrinsic fluorescent activity of the guest
(POM) and host (SBE-β-CD), respectively; [POM]E is the equilibrium
concentration of POM.
Since the equilibrium concentration of POM can be expressed in terms
of the total guest and the complex concentrations, Eq. (3) takes on the
following form:





IPOM can be calculated from the pure guest concentration and in-
tensity, while K and Icomplex should be calculated with nonlinear











All NMR measurements (1H NMR titrations, Job plot method) were
carried out on an Agilent Varian Unity Inova DDR spectrometer (599.9
MH for 1H) (Santa Clara, CA, USA) with a 5 mm inverse detection
gradient (IDPFG) probehead at 25 C. Standard pulse sequences and
processing routines available in VnmrJ 2.2 C/Chempack 4.0 were used.
Due to the poor solubility of POM, DMSO-d6 (10 v/v%) was added to the
D2O solution. During titrations, the POM concentration was kept con-
stant at 1 mM, while CD concentration gradually increased from 0 to 30
mM. For determination of the stability constant Eq. (5) was used:
δobs; ¼ δPOM
þ Δδ
½POMT þ ½CDT þ 1K 
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi






where. Δδ ¼ δPOMCD  δPOM
Stability constants (K) of the inclusion complexes were calculated by
non-linear parameter fitting of Eq. (4) to the δobs versus [CD]T datasets
using OriginPro 8 program based on previous work [18].
2.6. Molecular modeling
To explore the interaction of the S-enantiomer of POM and SBE-β-CD
at the molecular level, molecular modeling tools were applied. The exactFigure 2. 2D structures of S
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SBE-β-CD structure is unknown, because the sulfobutylether (SBE)
groups are randomly arranged on the β-CD skeleton and the CD itself is a
mixture of derivatives with different degrees of substitution. Therefore,
three different isomers were designed based on previous studies to mimic
different possible SBE-β-CD structures [19, 20]. It is known that the de-
gree of substitution of SBE-β-CD is ~7 and thus, the model structures
carry seven properly arranged SBE groups on the β-cyclodextrin skeleton
(Figure 2). The model structures have been prepared (energy minimi-
zation, OPLS-AA and Generalized Born implicit solvation model) and
used as hosts in molecular docking simulations. By using a “blind dock-
ing” protocol [21], the interactions between S-POM and the SBE-β-CD
isomers have been explored. AutoDock Vina was used to carrying out the
docking calculations [22]. The exhaustiveness, the maximum number of
binding modes, and the size of the grid box was set to 8, 9, and 30 30
30 Å, respectively. The most favorable S-POM-SBE-β-CD complex from
each calculation was selected and analyzed.
2.7. Preparation of physical mixture
Physical mixture (PM) was prepared by blending previously sieved
(125 mm) POM and SBE-β-CD (1:1 M ratio), in a ceramic mortar.
2.8. Preparation of POM - SBE-β-CD inclusion complex by lyophilization
Equimolar amounts of POM (0.1 M) and SBE-β-CD (0.1 M) were
dissolved in ethanol-water mixture (1:1 v/v ratio). The mixture was
stirred for 8 h at room temperature and filtered through a 0.45 mm
Millipore membrane filter. The yellow filtrate was frozen and then
lyophilized in a freeze-dryer (ScanVac CoolSafe freeze dryer, Labogene,
Denmark) for 24 h. The obtained powders were sieved (125 μm) and kept
in a desiccator until use.
2.9. Infrared spectroscopy
Infrared spectra (4000–400 cm1) of solid samples were recorded
using a Bruker Tensor 37 type Fourier transform infrared (FT-IR) spec-
trometer (Bruker Corporation, Billerica, MA, USA) equipped with DTGS
(deuterated triglycine sulphate) detector with a resolution of 4 cm1.
Before testing, the samples were mixed with potassium bromide (KBr)
powder and cold-pressed into a suitable disk for FT-IR measurement.
2.10. X-ray powder diffraction method
XRD of the samples were recorded by means of a PANalytical (Amelo,
the Netherlands) X'pert ProMDP X-ray diffractometer using Cu-Kα radi-
ation (1.542 Å) and a Ni filter. The applied voltage was 40 kV, while the
current was 30 mA. The samples were analyzed between 4 and 42 2ϴ.BE-β-CD model isomers.
Z.-I. Szabo et al. Heliyon 7 (2021) e075812.11. Real-time monitoring of dissolution using in situ UV probes
The POM concentration (both for the active pharmaceutical ingredient
and the complex) versus time (0–30min) profilewas investigatedat 25 0.1
C in Britton-Robinson buffer pH 7.0 and in simulated gastric fluid at pH ¼
1.6withUV-probes attached to theRainbowDynamicDissolutionMonitor of
the μDISS Profiler™ (Pion Inc., Billerica MA, USA). Powder samples,
equivalent to5mgofpurePOMwereweighed in20mLofappropriatebuffer.
2.12. Drug release kinetic
To analyze the profile of in vitro POM release from LP, the open source
KinetDS 3.0 software was used [23] following the method described by
Al-Qubaisi etal. [24]. The results of drug releasewerefitted tokineticmodels
of zero-order, first-order, second-order, Higuchi, Korsmeyer-Peppas, Wei-
bull, Hixson-Crowell and Michaelis–Menten [25]. The best-fit determines
the model that best described the drug release curve, mainly by the coeffi-
cient of determination (R2), empirical coefficient of determination (R2empir-
ical) (Eq. 6), Akaike information criterion (AIK) (Eq. 7), Bayesian information
































where yi:observed value, byi: model-predicted value, yAV : average output
vale.
2.13. Proliferation assay
The humanmyeloma cell line LP-1 was provided by the 1st Department
of Pathology and Experimental Cancer Research, Semmelweis University
(Budapest, Hungary). Cells were maintained in vitro as monolayer cultures
in RPMI-1640 medium supplemented with 5% FBS and antibiotic-
antimycotic solution at 37 C in a humidified 5% CO2 atmosphere. For
the proliferation assay, cells were seeded into 96-well plates at a density of
4000 cells/well containing either POM or the complex, each at various
concentrations (10-point dilution series of the compoundswere used in the
range of 0.6–300 μM). Control cells were incubated in culture media
without the active compound. The cells were incubated for 72 h and then a
colorimetric assay using MTT was performed to follow cell proliferation.
Briefly, 0.5 mg/mL of the dye MTT was added to the wells. After 4 h incu-
bation (37 C) the medium was gently removed, the plates were air-dried,
and the formazan crystals formed in viable cells were dissolved in DMSO.
The absorbance at 570 nm was measured with an Analyst GT multimode
reader (Molecular Devices, Sunnyvale, CA). The XLfit (IDBS) software was
used to generate the dose-effect curves for IC50 determination.
3. Results and discussion
3.1. Physico-chemical characterization of POM
As a preliminary investigation, the acid dissociation constant, the
partitioning coefficient, and the intrinsic solubility of POM were4
determined. The obtained data are summarized in Table 1. From the
results, it is notable that there is a second pKa for POM with a predicted
value of around eleven (the authors found no previous work in the
literature describing this parameter based on experimental data). How-
ever, due to the poor solubility of the compound in basic media, this
parameter was not measurable using 1H NMR titration. Moreover, the
second pKa has not much real practical significance because of the
decomposition of POM in basic media. The molecule is in its neutral form
in a wide pH range, and it is in its protonated form only in very acidic pH
values. The obtained data indicate low solubility and low lipophilicity,
which is independent of pH. Our data seems to underline the inclusion of
POM as a BCS class IV drug [3, 26]and justified the application of CD
complexation to increase POM solubility.
3.2. Phase-solubility study
Phase-solubility studies are commonly applied to characterize CD
complexation in a liquid state. This technique offers valuable information
on stoichiometry and complex stability. In the present phase-solubility
study, the complexation of POM with nine different CD derivatives was
investigated in water. Three native CDs were chosen to select the
appropriate cavity size for inclusion of POM. Among synthetic β-CD de-
rivatives the most commonly used ones were selected, which are official
in the Pharmacopoeias (HP-β-CD, SBE-β-CD) or approved as excipients in
pharmaceutical products intended for human use (RAMEB) [27].
Furthermore, another frequently employed, well-characterized, methyl-
ated derivative (TRIMEB) was also studied. In all cases AL-type phase
solubility diagrams were observed. As the slope of the curve is less than 1
1:1 binding stoichiometry can be assumed. The calculated stability con-
stants based on Eq. (1) and the obtained solubility enhancements are
summarized in Table 2, while some representative phase solubility plots
are depicted in Figure 3.
Table 2 shows that the most stable complex with the native CDs is
formed with β-CD, indicating that it has the most suitable cavity size for
POM, while the complex stability with α-CD is the lowest. Among the
tested CD derivatives, only HP-β-CD with DS 4.5 and SBE-β-CD presented
higher complex stability with POM than the native β-CD. Interestingly,
when comparing the HP-β-CDs with different DSs, the highest stability
constant was found with the DS 4.5. Both a decrease and increase in DS
lead to a decrease in complex stability. This could be explained by an
overall higher strength of interaction with an increase of DS from 3 to
4.5. However, a further increase in the number of substituents per CD
molecule might lead to overcrowding and lowers the strength of in-
teractions during inclusion complexation. These results further underline
the need to use well-characterized CDs, especially with regard to their DS
[28]. Based on our data, methylation of β-CD decreased the complex
stability, however this effect is spectacular in the case of TRIMEB. It can
be seen that RAMEB forms a three-times more stable complex with POM
than TRIMEB. Orgovan et al. observed a similar phenomenon when
studying clotrimazole CD complexation [29]. Based on our measure-
ments SBE-β-CD was the most suitable host for POM, as it presented the
highest complex stability with POM, therefore, this derivative was cho-
sen for further characterization. In a previous study Kale et al. used
SBE-β-CD for molecular encapsulation of the parent drug thalidomide
with SBE-β-CD to increase its bioavailability [13]. It should be noted that
our study is the first to compare the solubility enhancement of one of the
thalidomide-derivatives.
3.3. NMR Job plot
Job's continuous variation method was adopted to verify the stoi-
chiometry of the POM-SBE-β-CD inclusion complex. In this experiment,
the 1H NMR chemical shifts (δ) were measured at different POM con-
centration/SBE-β-CD concentration ratios, while the sum of cPOM þ cSBE-
B-CD was kept constant. The calculated factors (ΔδχPOM) were plotted as a
function of POM molar ratio (χPOM). The resulting Job plot diagrams
Table 1. Results of physico-chemical characterization of POM (mean SD, n¼ 3).
Physico-chemical parameter Obtained value
Protonation macroconstant (pKa) 1.89  0.01
Partitioning coefficient (logP) 0.01  0.05
Intrinsic solubility (S0) 4.51  0.11 mg/L
Table 2. The calculated stability constants and the achieved solubility
enhancement based on phase solubility study.
Cyclodextrin K (mean  SD, n ¼ 3) Maximum solubility
enhancement
(CD concentration)
α- 2.7  0.5 1.10  (30mM)
β- 97.2  3.1 2.16  (11.8 mM)
γ- 30.3  0.8 1.70  (30 mM)
HP-β- DS 3 68.5  1.1 3.27  (30 mM)
HP-β- DS 4.5 129.9  2.2 4.66  (30 mM)
HP-β- DS 6 87.7  2.8 3.69  (30 mM)
RAMEB 101.7  1.7 3.75  (30mM)
TRIMEB 24.0  0.6 1.74  (30mM)
SBE-β-CD DS 7 194.6  1.0 6.93  (30mM)
Figure 3. Some representative phase solubility diagrams of POM with
different CDs.
Figure 4. Representative Job plot curves of POM with SBE-β-CD.
Z.-I. Szabo et al. Heliyon 7 (2021) e07581showedmaxima at 0.5 for all investigated protons, indicating 1:1 binding
stoichiometry in accordance with phase solubility results. Representative
Job plot curves are shown in Figure 4.Table 3. Comparison of POM-SBE-β-CD stability constant (logK) determined by
different method (mean  SD, n ¼ 3).
Phase solubility Fluorescence Circular dichroism NMR** CE***
1* 2.29  0.03 2.31  0.01 2.44  0.06 2.08  0.01 2.37  0.01
2* 2.25  0.01 2.42  0.02
* Enantiomer-specific value (First and second enantiomer, respectively).
** Determined in DMSO/water mixture.
*** Literature value [8] pH ¼ 6.5 in 50 mM Tris-acetate buffer.3.4. Determination of POM-SBE-β-CD stability constant using different
spectroscopic techniques
Although the phase-solubility method is one of the easiest and most
employed technique for the characterization of inclusion complexes, it
should also be noted that the phase solubility plot can only be used to
estimate complex stoichiometry, especially for substances with poor
solubility [30, 31]. Therefore, alternative techniques such as fluores-
cence-, circular dichroism-, and NMR spectroscopy, were also applied to
determine the stability constant of POM-SBE-β-CD complexes. The
measured stability constants were compared with our earlier published
data obtained with capillary electrophoresis [8]. The results were sum-
marized in Table 3.
The stability constants are in good agreement with each other. It can
be observed that the complex is characterized by moderate stability5
sufficient to potentially increase POM solubility. The experiments per-
formed to provide an opportunity to compare the five different tech-
niques. The smallest stability constant was measured by NMR. Due to the
low solubility of POM in water, DMSO was applied to reach the appro-
priate concentration for NMR measurement. DMSO interacts with CDs,
which might be one of the reasons for the lowest recorded value [32]. On
the other hand, NMR and capillary electrophoresis are also suitable for
the determination of enantiospecific complex stability constants. POM is
a racemic mixture that exists in two enantiomeric forms. The
phase-solubility method, circular dichroism and fluorescence spectros-
copy are not capable to distinguish between the enantiomers, the ob-
tained values are averaged for the two enantiomer-CD complexes. The
advantage of circular dichroism study in the case of racemic compounds
is that the induced circular dichroism signal is directly proportional with
complex formation. Fluorescence spectroscopy on the other hand is a
simple, fast method and it is the most sensitive one, for the character-
ization of inclusion complexation.3.5. Molecular modeling study of the POM-SBE-β-CD inclusion complex
Docking simulations were used to study the geometric aspects of the
complexation of S-POM and SBE-β-CD. The 3D structures of the com-
plexes of S-POM and three different SBE-β-CD model isomers together
with the corresponding EA values (binding affinities) can be seen in
Figure 5. The binding affinities were between -6.4 to -7.4 kcal/mol,
indicating that complex formation is thermodynamically favored
regardless of the applied isomer. However, isomer 1 was less favored
than the other two SBE-β-CD model structures. Thus, although S-POM
formed a complex with the SBE-β-CD isomers, the stability values of the
complexes are different. To further investigate this phenomenom, single
isomer CDs would be necessary. From a structural point of view, it can be
observed that the glutarimide moiety of POM is inside the CD cavity in all
cases, while the phthalimide part of the molecule interacts with the SBE-
Figure 5. 3D structures of S-POM-SBE-β-CD complexes with the calculated binding affinities (EA, kcal/mol).
Figure 6. X-ray powder diffraction pattern of POM, SBE-β-CD, PM, and LP.
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β-CD isomers through its primary amine group, which keeps it closer to
the CD skeleton.3.6. Solid-state characterization of complex
Apart from the liquid state characterization, solid complexes were
also prepared by lyophilization and further analyzed by complementary
solid-state techniques.
3.6.1. X-ray powder diffraction
The results of the XRD analysis are shown in Figure 6. The sharp
diffraction peak of POM at 12.4, 14.1, 17.4, 18.5, 24.5, 25, 25.6,
and 28.2 indicates its crystalline nature. SBE-β-CD exhibits a diffuse
halo pattern without distinct peaks due to its amorphous nature. The
powder diffraction pattern of the PM was basically the superposition
of SBE-β-CD and POM diffraction patterns, indicating that simple
mixing did not induce complexation of the active. The lower intensity
POM peak in the physical mixture is due to the relatively low POM
Figure 7. Comparative FT-IR spectra of POM, SBE-β-CD, PM, and LP. Arrows
show differences in the obtained FT-IR spectra.
Z.-I. Szabo et al. Heliyon 7 (2021) e07581content in the mixture. Simple mixing did not induce interactions
between POM and the applied CD. On the other hand, the XRD anal-
ysis of LP clearly shows that the inclusion complex is totally in the
amorphous state, no sign of crystalline character is present on this
diffraction pattern.
3.6.2. FT-IR
Solid state characterization of POM-SBE-β-CD complexation was un-
dertaken by analyzing the FT-IR spectra of POM, SBE-β-CD, their physicalFigure 8. The dissolution profile of POM a
Figure 9. Kinetic models of POM
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mixture (PM) and the lyophilized product (LP). FT-IR is widely applied
for solid state characterization of CD complexes, by tracking the distur-
bances in vibrational modes through complexation as a window to
decipher possible host-guest interactions. Usually disappearing or
broadening of peaks, intensity variations or shifts in wavenumber can
indicate the complex formation [33]. Figure 7 shows the overlay of the
obtained FT–IR spectra.
POM has a complex fingerprint region of the IR spectra due to the
presence of heterocycles. The two intense twin bands at 3475 cm1 and
3370 cm1 (aniline N–H stretch), together with the highest intensity
peak at 1700 cm1 (C¼O stretch) are characteristic for the compound.
FT-IR spectra of SBE-β-CD showed a few characteristic absorption peaks,
in line with literature data [34], including a strong band at 3423 cm1
(O–H stretching), 2938 cm1 (C–H stretching), 1161 cm1 (C–H vibra-
tions) and 1043 cm1 (C–O stretching). The FT-IR spectra of the PM is a
superposition of the spectra of the two individual components. However,
when comparing the lyophilized product (LP) with the PM, several dif-
ferences can be observed. The disappearance of the POM peaks at 1700
cm1 (C¼O stretch) and the twin peaks at 3475 cm1 and 3370 cm1
(aniline N–H stretch), alongside with prominent peak broadening both at
the O–H stretch (3423 cm1) 1161 cm1 and 1043 cm1 (C–O stretch) of
the CD confirm the presence of secondary interactions in solid state,
presumably between the carbonyl groups of POM and the SBE-β-CD hy-
droxyl groups.
3.7. Dissolution study
The dissolution profile of the examined POM and LP was followed in
real-time via UV fiber-optic probes at two pHs. LP resulted in marked
improvement of POM dissolution rate with respect to the drug alone
regardless of pH. At pH 7, the dissolution kinetics were highly different,nd LP at pH ¼ 1.6 (A) and pH ¼ 7 (B).
release from LP at pH ¼ 1.6.
Figure 10. Kinetic models of POM release from LP at pH ¼ 7.
Z.-I. Szabo et al. Heliyon 7 (2021) e07581the lyophilized product reached the maximum concentration almost
instantaneously, while the neat active ingredient needed 20 minutes to
form a saturated solution (Figure 8). The equilibrium solubilities in these
two cases were also different, the solution of the LP had almost 10 μg/mL
concentration, which is more than 1.5 times higher, than the equilibrium
concentration of the neat POM. At pH ¼ 1.6 the difference between the
LP and POMwas not as conspicuous, as in the case of the measurement at
pH ¼ 7. But the LP reached the equilibrium concentration faster (1 min)
than the POM (5 min) and also had a higher equilibrium solubility than
the neat active ingredient (Figure 8A). It is also noteworthy that the
intrinsic pharmacokinetic parameters of weakly and moderately bound
guest molecules (Ks<10000 M1) is unaltered by CD complexation [35].
Thus, it can be assumed, that inclusion complex formation in case of
POM-SBE-β-CD would not impact the pharmacokinetics of the active,
only its solubility and implicitly its bioavailability.
To analyze the profile of drug release from LP, KinetDS 3.0 software
was used [23]. The results of POM release at both pHs were fitted to
eight different kinetic models as seen in Figures 9 and 10. The AIK, BIC,Table 4. Results of data fitting for POM release from LP at pH ¼ 1.
Model Slope Intercept R2 R
Zero-order 0.2029 6.3709 0.3996 0
First-order 0.0502 1.5327 0.1534 -0
Second-order -8.506 1.2473 0.0406 -4
Korsmeyer-Peppas 0.2092 1.7354 0.8507 0
Weibull 16.952 0.2115 0.8502 0
Hixson-Crowell 0.0237 1.7685 0.2390 0
Higuchi 0.5000 1.4479 -5.033 -5
Michelis-Menten 1.9*109 0.1676 0.9898 -0
Table 5. Results of data fitting for POM release from LP at pH ¼ 7.
Model Slope Intercept R2 R
Zero-order 0.02650 9.2429 0.3492 0
First-order 0.00287 2.2222 0.3005 0
Second-order 0.00031 0.1085 0.2556 0
Korsmeyer-Peppas 0.01203 2.2406 0.9948 0
Weibull 0.01260 -2.3154 0.9946 0
Hixson-Crowell 0.00201 2.0979 0.3163 0
Higuchi 0.50000 1.8254 -873.9 -8
Michelis-Menten 3.5*1012 0.1046 0.8516 0
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and RSME values were the best for describing the release kinetics of
POM from the LP (Table 4 and Table 5). The kinetic models that best
described the dissolution profiles were the Korsmeyer-Peppas and
Weibull model. There is no significant difference between these two
models and both were used previously to evaluate the kinetic release
from inclusion complexes or from other matrix-type drug delivery
system [24, 36].3.8. In vitro antiproliferative assay
Some studies suggest that CD complexation can improve the phar-
macodynamic properties of drugs, including anticancer agents as well
[37, 38]. However, it should be noted that the use of CD is intended to
increase the solubility of pharmaceuticals. The antiproliferative activity
of POM, PM and LP was assessed by IC50 measured on human myeloma
cell line LP-1, which has previously been shown to be adequate to study
the antitumor activity of POM [39]. The determined IC50 value for POM
(33.28μM  5.2), LP (37.28μM  7.3), and PM (39.29μM  8.5)2
emp. RMSE AIC BIC k
.3996 1.6211 253.820 257.663 -
.1382 2.2314 286.392 290.255 -
7.38 14.552 477.652 481.516 -
.6943 1.1567 219.371 223.234 5.67
.7128 1.1211 216.185 220.048 16.9
.2694 1.7882 263.806 267.670 0.02
.033 5.1387 371.477 375.341 4.25
.8082 2.8133 310.027 313.890 1.2*108
2
emp. RMSE AIC BIC k
.3492 0.3396 70.260 73.735 -
.3454 0.3406 70.508 73.983 -
.3387 0.3423 70.829 74.405 -
.9936 0.0366 -123.92 -120.453 9.40
.9934 0.0341 -122.76 -119.291 10.13
.3469 0.3402 70.409 73.884 0.002
73.9 12.451 372.814 376.289 6.21
.7655 0.2039 27.391 30.866 3.4*1011
Z.-I. Szabo et al. Heliyon 7 (2021) e07581indicating that complex formation did not significantly affect the anti-
cancer effect of the thalidomide-analogue. However, it should be noted
that thalidomide administered orally in combination with SBE-β-CD, led
to a significant delay in tumor formation as a result of improved cellular
drug absorption, distribution through solubilization in mice [13].
4. Conclusion
The physico-chemical profiling of POM was described for the first
time and results underlined that the blockbuster drug is characterized by
low solubility and low lipophilicity, which is independent of pH, which
underlines the inclusion of POM as a BCS class IV drug. The present work
also described the first method for solubility improvement of POM via CD
complexation. Among the nine different CD derivatives tested, the most
promising host molecule was revealed to be SBE-β-CD.
The binary system between POM and SBE-β-CD was fully character-
ized in liquid and solid state by state-of-art analytical techniques and
molecular modelling. The inclusion complex formation resulted in
significantly improved solubility, immediate release of the active without
decreased antiproliferative activity. Using CD complex formation
applying SBE-β-CD as host seems promising cheap, simple environmen-
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